CN119161480A - 用于治疗的药剂、用途和方法 - Google Patents

用于治疗的药剂、用途和方法 Download PDF

Info

Publication number
CN119161480A
CN119161480A CN202411383695.6A CN202411383695A CN119161480A CN 119161480 A CN119161480 A CN 119161480A CN 202411383695 A CN202411383695 A CN 202411383695A CN 119161480 A CN119161480 A CN 119161480A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411383695.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·C·比尔曼勒恩
I·J·马里克
J·B·斯塔文哈根
S·克里斯滕森
J·埃格比约
T·斯图曼
A·格里森
E·范登布林克
P·帕伦
E·特拉伯格
K·D·兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN119161480A publication Critical patent/CN119161480A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411383695.6A 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法 Pending CN119161480A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201700419 2017-07-20
DKPA201700419 2017-07-20
CN201880047918.8A CN110945029B (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法
PCT/EP2018/069460 WO2019016247A2 (en) 2017-07-20 2018-07-18 AGENTS, USES AND METHODS OF TREATMENT

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880047918.8A Division CN110945029B (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法

Publications (1)

Publication Number Publication Date
CN119161480A true CN119161480A (zh) 2024-12-20

Family

ID=63113476

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411383695.6A Pending CN119161480A (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法
CN201880047918.8A Active CN110945029B (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法
CN202411383796.3A Pending CN119161481A (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880047918.8A Active CN110945029B (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法
CN202411383796.3A Pending CN119161481A (zh) 2017-07-20 2018-07-18 用于治疗的药剂、用途和方法

Country Status (25)

Country Link
US (2) US10894833B2 (enExample)
EP (1) EP3655438A2 (enExample)
JP (2) JP7563975B2 (enExample)
KR (1) KR102800556B1 (enExample)
CN (3) CN119161480A (enExample)
AR (1) AR112563A1 (enExample)
AU (1) AU2018303175B2 (enExample)
BR (1) BR112019005428A2 (enExample)
CA (1) CA3069391A1 (enExample)
CL (1) CL2020000070A1 (enExample)
CO (1) CO2019014090A2 (enExample)
CR (1) CR20200027A (enExample)
DO (1) DOP2020000006A (enExample)
EA (1) EA201992688A1 (enExample)
EC (1) ECSP20002935A (enExample)
IL (1) IL271728B2 (enExample)
JO (1) JOP20200007A1 (enExample)
MA (1) MA49633A (enExample)
NI (1) NI202000005A (enExample)
PE (1) PE20210467A1 (enExample)
PH (1) PH12019502869A1 (enExample)
RU (1) RU2019140933A (enExample)
SG (1) SG11201912228WA (enExample)
TW (1) TW201908342A (enExample)
WO (1) WO2019016247A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3280441T3 (pl) 2015-04-07 2022-02-21 Alector Llc Przeciwciała przeciwko sortilinie i sposoby ich stosowania
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11396546B2 (en) 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
WO2020252066A1 (en) * 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
KR20230026489A (ko) * 2020-06-24 2023-02-24 프로테나 바이오사이언시즈 리미티드 소르틸린을 인지하는 항체
JP2025530891A (ja) 2022-06-23 2025-09-18 ドラウプニル バイオ エーピーエス リソソーム内の細胞外標的の分解を選択的に誘導する二機能性分子

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
DK3225251T3 (da) 2006-12-21 2020-03-16 H Lundbeck As Modulering af pro-neurotrofinaktivitet
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
ES2596360T3 (es) * 2008-01-16 2017-01-09 Neurodyn Life Sciences Inc. Progranulina para su uso en el tratamiento de enfermedad de Parkinson o enfermedad de Alzheimer
US8377701B2 (en) 2008-04-27 2013-02-19 H. Lundbeck A/S Specific ligands to sortilin
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN102439041B (zh) 2008-12-19 2016-05-04 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
US10149836B2 (en) * 2014-03-21 2018-12-11 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
KR102555955B1 (ko) * 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
PL3280441T3 (pl) 2015-04-07 2022-02-21 Alector Llc Przeciwciała przeciwko sortilinie i sposoby ich stosowania
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP2020513009A (ja) * 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
US11396546B2 (en) * 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
CN113151432A (zh) * 2020-04-14 2021-07-23 郁金泰 神经退行性疾病检测和治疗的新靶标

Also Published As

Publication number Publication date
AR112563A1 (es) 2019-11-13
PE20210467A1 (es) 2021-03-08
ECSP20002935A (es) 2020-02-28
CA3069391A1 (en) 2019-01-24
US20190023788A1 (en) 2019-01-24
EP3655438A2 (en) 2020-05-27
IL271728B1 (en) 2024-01-01
AU2018303175A1 (en) 2020-01-16
RU2019140933A3 (enExample) 2021-10-28
JP2020527152A (ja) 2020-09-03
KR102800556B1 (ko) 2025-04-24
TW201908342A (zh) 2019-03-01
CR20200027A (es) 2020-04-17
US20210292414A1 (en) 2021-09-23
PH12019502869A1 (en) 2020-09-28
WO2019016247A2 (en) 2019-01-24
SG11201912228WA (en) 2020-01-30
NI202000005A (es) 2020-05-20
KR20200031610A (ko) 2020-03-24
AU2018303175B2 (en) 2025-01-23
CN110945029B (zh) 2024-10-01
RU2019140933A (ru) 2021-08-20
US10894833B2 (en) 2021-01-19
JP7563975B2 (ja) 2024-10-08
CL2020000070A1 (es) 2020-06-12
CN110945029A (zh) 2020-03-31
CN119161481A (zh) 2024-12-20
DOP2020000006A (es) 2020-07-15
BR112019005428A2 (pt) 2019-07-16
JOP20200007A1 (ar) 2020-01-15
MA49633A (fr) 2020-05-27
IL271728B2 (en) 2024-05-01
WO2019016247A3 (en) 2019-06-20
CO2019014090A2 (es) 2020-01-17
JP2024119866A (ja) 2024-09-03
EA201992688A1 (ru) 2020-05-20
IL271728A (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US12331123B2 (en) Agent, uses and methods for treatment
CN110945029B (zh) 用于治疗的药剂、用途和方法
HK1254356B (en) Antibodies that bind to sortilin and inhibit the binding of progranulin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination